FDA approves budesonide oral suspension for treatment of eosinophilic esophagitis
The Food and Drug Administration (FDA) has approved EOHILIA (budesonide) oral suspension for treatment of eosinophilic esophagitis among adults and pediatric patients 11 years of age and older. It will be available in 2 mg/10 mL convenient, single-dose stick packs by the end of February. EOHILIA is a corticosteroid indicated for 12 weeks of treatment […]